



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:) Confirmation No. 1789
Frederic J. de SAUVAGE, et al.) Examiner: HAYES, Robert Clinton
Application Serial No. 10/621,855) Art Unit: 1653
Filed: July 16, 2003) Attorney's Docket No. 39766-0065 DV1
For: GFR α 3 AND ITS USES) Customer No. 25213
)
)

EXPRESS MAIL LABEL NO. EV 765 988 891 US

DATE MAILED: December 13, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

MAIL STOP AMENDMENT

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450


Sir:

Applicants wish to bring to the attention of the Patent Office the references listed on the attached Form PTO-1449 and request that the listed information be considered by the Examiner and be made of record in the above-identified application. Each of the references listed on the attached Form PTO-1449 was previously cited by or submitted to the PTO in prior Application Serial No. 09/272,835. Since all references were previously cited by or submitted to the PTO, no references are enclosed.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b)(3), therefore no fee is due. The Commissioner is hereby authorized to charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641, referencing Attorney's Docket No. 39766-0065 DV1.


Respectfully submitted,

By:


James A. Fox (Reg. No. 38,455)

Dated: December 13, 2005

HELLER EHRLMAN LLP
275 Middlefield Road
Menlo Park, California 94025-3506
Telephone: (650) 324-7000
Facsimile: (650) 324-0638



| Form PTO-1449 INFORMATION DISCLOSURE STATEMENT <i>(use several sheets if necessary)</i> | | | | Attorney's Docket No. 39750-0065DV1 | Application Serial No. 10/621,855 | | |
|---|----------|---|--------------|---|---|----------|------------------------------|
| | | | | Applicant(s) Frederic J. de SAUVAGE, et al. | | | |
| | | | | Filing Date: July 16, 2003 | Group Art Unit: 1653 | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Filing Date (if appropriate) |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| Examiner Initials | Ref. No. | Date | Document No. | Name | Class | Subclass | Translation YES NO |
| | | | | | | | |
| OTHER DOCUMENTS <i>(including author, title, date, pertinent pages, etc.)</i> | | | | | | | |
| Examiner Initials | Ref. No. | Title | | | | | |
| | 1 | Andres et al., <i>Development</i> 128(10):3685-3695 (2001) Multiple effects of artemin on sympathetic neurone generation, survival and growth | | | | | |
| | 2 | Baloh et al., <i>Neuron</i> 21: 1291-1302 (1998) Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex | | | | | |
| | 3 | Esteva, "Monoclonal Antibodies, Small Molecules, and Vaccines in the Treatment of Breast Cancer," <i>The Oncologist</i> 9(Suppl 3):4-9 (2004), page 6, column 1, lines 8-16). | | | | | |
| | 4 | Negro et al., <i>Recent Prog Horm Res.</i> 59:1-12 (2004) Essential roles of Her2 erbB2 in cardiac development and function | | | | | |
| | 5 | Rosická et al., <i>Physiological Research</i> 51:435-441 (2002) Ghrelin - a New Endogenous Growth Hormone Secretagogue/ | | | | | |
| | 6 | Smith et al., <i>Best Pract Res Clin endocrinol Metab.</i> 18(3):333-347 (2004) Growth hormone secretagogues: prospects and potential pitfalls | | | | | |
| | 7 | Thilenius et al., <i>Eur. J. Immunol.</i> 27(5):1108-1114 (1997) Agonist antibody and Fas ligand mediate different sensitivity to death in the signaling pathways of Fas and cytoplasmic mutants | | | | | |
| EXAMINER: | | | | DATE CONSIDERED: | | | |
| EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant. | | | | | | | |
| *If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d). | | | | | | | |